A peptide COA is a certificate of analysis: a lot-specific quality record, not a blanket safety promise or an FDA approval. For BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500 used under HHS’s interim 503A policy, the record now has to do much more than show a high purity percentage: it must connect the exact peptide and lot to the original registered manufacturer, its facility location, and the required quality testing.
| COA means | Certificate of analysis for a specific bulk-drug-substance lot. |
| Six HHS peptides | BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500. |
| Key COA checks | Exact identity, purity and potency; endotoxin and other quality testing; batch and release details; manufacturer and facility details. |
| Human compounding grade | The COA must state “Intended for human drug compounding.” |
| What it does not mean | The compounded drug is not FDA-approved. |
What changed for peptide COAs?
October 28, 2026
HHS’s peptide policy now sets specific conditions for a narrow interim enforcement-discretion pathway while final rulemaking on these substances continues. HHS lists six peptides in Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500. OIRA completed review of the policy on October 27, 2026, with the conclusion “Consistent with Change.” A Federal Register publication on October 30 has been reported, but the policy document itself does not state that publication date.
This is not a general green light for peptide vials. HHS says it does not intend to take action against a state-licensed pharmacy, federal facility, or licensed physician compounding one of the six peptides only when every policy condition is met. Compounded drugs are not FDA-approved; FDA’s compounding Q&A explains that FDA does not verify their safety, effectiveness, or quality before marketing.
How do you read a peptide COA under the HHS policy?
Start by treating the COA as a record for one identifiable lot, not as a generic marketing badge. The material name, chemical form, batch number, manufacturer, test methods, and release details should all describe the same bulk substance the 503A compounder received.
| COA item | What HHS requires or expects | Why it matters |
|---|---|---|
| Identity | The exact peptide identity and results consistent with FDA guidance-based criteria. | A familiar peptide name alone is not enough; the policy ties eligibility to the specified identity. |
| Purity and potency | Results supporting identity, purity, potency, and characterization. | Purity is one quality result, not a substitute for the other listed tests. |
| Contaminant testing | Testing includes endotoxins, heavy metals, microbial contamination, and impurities. Appendix B also lists items such as residual solvents, elemental impurities, residual TFA, water content, and bioburden where applicable. | Each result answers a different quality question. |
| Manufacturer and site | The original manufacturer—not merely a later packer, repacker, labeler, or distributor—must be FDA-registered under section 510, CGMP-compliant, and named on the COA with its FEI number and address. | You can trace the bulk lot back to the original manufacturing facility. |
| Lot and release record | Batch number, synthesis date, release date, and expiration or retest date. | These details connect the document to a defined production lot and period. |
| Grade and quality sign-off | The stated grade “Intended for human drug compounding” and a CGMP statement signed by the quality unit. | This distinguishes the policy’s compounding-grade record from research-use-only marketing. |
HHS also requires appropriate validation when the bulk substance comes through an FDA-registered repacker, relabeler, or reseller: that business must document validation of both the original manufacturer and the manufacturer’s COA. Ask the pharmacy or prescriber to explain that chain for the specific lot rather than relying on a document that is not tied to the ingredient used.
Which forms and routes are within this policy?
The policy is substance- and route-specific. A COA does not expand those limits.
| Peptide | HHS policy route limit |
|---|---|
| BPC-157 acetate | Subcutaneous, intramuscular, oral, and topical. |
| TB-500 acetate | Subcutaneous or intramuscular injection. |
| MOTS-c acetate | Subcutaneous or intramuscular injection. |
| Epitalon acetate | Subcutaneous or intramuscular injection in intermittent courses. |
| Semax free base | Intranasal only. |
| KPV acetate | Topical and oral only. |
For an oral form, HHS expects the compounder to maintain documentation that the specific formulation achieves adequate oral bioavailability in humans. The only device allowed to be co-packaged with or contained in the compounded product is an FDA 510(k)-cleared syringe.
Can a research-use-only vial qualify?
No. HHS says its policy is intended to discourage research-use-only peptides supplied by foreign manufacturers. A research-use-only vial is outside this pathway. So are combination vials containing two or more peptides, GHK-Cu, and peptides that are not on Appendix A.
The policy requires a single active pharmaceutical ingredient from the six-peptide list. That gives you a simple answer to “what should you not mix with peptides?” in this setting: a compounded product under this policy cannot combine two or more peptide APIs. It also requires a valid patient-specific prescription, reporting of serious adverse events and product-quality issues to FDA MedWatch and relevant states, and the label statement: “This is a compounded drug product. Not for resale.”
Does a high purity number settle the safety question?
No. A purity result addresses purity under its stated method. HHS separately calls for identity, potency, impurity, endotoxin, microbial, and other characterization results, because those are distinct quality questions. The policy also says HHS may revisit its approach if a safety signal or product-quality issue arises.
FDA’s category-2 page previously described potential concerns for these substances, including peptide-related impurities, aggregation, and limited safety information for several of them. HHS notes that all six were in category 2 from September 2023 until April 22, 2026; CDER recommended against listing them, while the Pharmacy Compounding Advisory Committee voted in favor. A policy pathway for compounding is therefore not the same as FDA approval or a conclusion that every product is appropriate for every person.
What are your realistic options?
If you are considering one of these six peptides, the policy points to three distinct paths:
- Discuss a patient-specific prescription with a prescriber and use a state-licensed 503A pharmacy operating within every HHS condition, including the route and COA requirements.
- Discuss FDA-approved peptide drugs when an approved option fits the health question you are trying to address.
- Wait for final rulemaking on each substance’s place on the 503A bulks list.
For online prescription offers, FDA online-pharmacy guidance says safer signs include a prescription requirement, a U.S. address and phone number, a licensed pharmacist who can answer questions, and state-board licensing. Bring your medication list and health history to the prescriber or pharmacist before adding any prescription drug.
How does this differ from a C-peptide test?
They share a word but answer different questions. On this page, CoA means certificate of analysis for a peptide bulk-substance lot. A C-peptide serum test is a separate laboratory-test topic; ask the clinician or laboratory that ordered it to explain what that specific result measures.
Before you rely on a peptide COA
- Match the exact peptide form and batch number to the compounder’s record.
- Ask whether the original manufacturer is FDA-registered, CGMP-compliant, and identified with its FEI number and facility address on the COA.
- Look for identity, purity, potency, endotoxin, microbial, impurity, and other applicable test results—not just one HPLC percentage.
- Confirm the grade reads “Intended for human drug compounding,” with a signed quality-unit CGMP statement.
- Confirm the prescription, single-API formulation, and route fit the HHS policy conditions.
For broader context on research-only seller language, see synthesis peptides reviews and loti labs peptides alternatives.
By The Nerve & Joint Pain Desk Editorial Team
Keep reading